Trial Profile
A prospective, randomized, monocentric, rater blinded study evaluating the change of the cutaneous microbiome in correlation to the efficacy of cold atmospheric plasma treatment in comparison to diclofenac 3% in 2.5% hyaluronic acid (Solaraze 3% Gel) in patients with actinic keratoses - ACTICAP
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2019
Price :
$35
*
At a glance
- Drugs Diclofenac/hyaluronic-acid (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Acronyms ACTICAP
- 16 Dec 2019 Status changed from recruiting to completed.
- 13 Dec 2017 New trial record
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.